S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

• C. Touzeau,
• A. Krishnan,
• P. Moreau,
• A. Perrot,
• S. Z. Usmani,
• S. Manier,
• M. Cavo,
• C. Martinez-Chamorro,
• A. Nooka,
• T. Martin,
• L. Karlin,
• X. Leleu,
• N. Bahlis,
• B. Besemer,
• L. Pei,
• R. Verona,
• S. Girgis,
• C. Uhlar,
• R. Kobos,
• A. Garfall

Affiliations

C. Touzeau

1 University Hospital Hôtel-Dieu, Nantes, France

A. Krishnan

2 City of Hope Comprehensive Cancer Center, Duarte, United States of America

P. Moreau

1 University Hospital Hôtel-Dieu, Nantes, France

A. Perrot

3 Centre Hospitalier, Universitaire de Toulouse, Service d’Hematologie, Toulouse, France

S. Z. Usmani

4 Levine Cancer Institute/Atrium Health, Charlotte, United States of America

S. Manier

5 University of Lille, Lille, France

M. Cavo

6 IRCSS Aziena Ospedaliero-Universitaria di Bologna, Bologna University School of Medicine, Bologna, Italy

C. Martinez-Chamorro

7 University Hospital Quirónsalud, Pozuelo de Alarcón, Madrid, Spain

A. Nooka

8 Winship Cancer Institute, Emory University, Atlanta

T. Martin

9 University of California, San Francisco, San Francisco, United States of America

L. Karlin

10 Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite

X. Leleu

11 Centre Hospitalier Universitaire de Poitiers, Poitiers, France

N. Bahlis

12 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada

B. Besemer

13 University of Tuebingen, Tuebingen, Germany

L. Pei

14 Janssen Research & Development, Raritan

R. Verona

15 Janssen Research & Development, Spring House

S. Girgis

15 Janssen Research & Development, Spring House

C. Uhlar

15 Janssen Research & Development, Spring House

R. Kobos

14 Janssen Research & Development, Raritan

A. Garfall

16 Abramson Cancer Center, Perelman School of Medicine, Philadelphia, United States of America